Boston Life Sciences (MM) News - BLSI

Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.

HOPKINTON, Mass., June 8 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSINASDAQ:andNASDAQ:ALSE) today announced that its...

Boston Life Sciences, Inc. Announces Webcast of 2007 Annual Meeting

HOPKINTON, Mass., June 5 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that the Company will provide a...

Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program

Key Thought Leaders in the Area of Spinal Cord Injury Research to Advise on Cethrin(R) Development Program HOPKINTON, Mass., May 29...

Boston Life Sciences to Host 2007 1st Quarter Conference Call

HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that they will host a conference call...

Boston Life Sciences Raises $6 Million Through Issuance of a Convertible Promissory Note to a New Fund

HOPKINTON, Mass., May 3 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that it entered into an amendment to...

Boston Life Sciences, Inc. to Present at the 2007 Biotechnology Industry Organization's (BIO) Annual BIO International Conventio

HOPKINTON, Mass., May 1 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Ken Rice, Executive Vice...

Boston Life Sciences Reports New Option Grants Under NASDAQ Market Rule 4350

HOPKINTON, Mass., April 17 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) announces, in accordance with NASDAQ Marketplace...

Boston Life Sciences, Inc. Announces Presentation of Cethrin(R) Phase I/IIa 6-Month Results at 75th Annual Meeting of the Americ

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level HOPKINTON, Mass., April 16 /PRNewswire-FirstCall/ -- Boston Life Sciences...

Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer

Veteran Pharmaceutical Executive Will Lead BLSI's Business Development Efforts HOPKINTON, Mass., April 16 /PRNewswire-FirstCall/ -- Boston Life...

Boston Life Sciences, Inc. Announces Data to be Presented on Cethrin(R) for Spinal Cord Injury at the 2007 American Association

HOPKINTON, Mass., April 12 /PRNewswire-FirstCall/ -- Boston Life Sciences (NASDAQ:BLSI), a biopharmaceutical company focused on the research and...

Boston Life Sciences, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K

HOPKINTON, Mass., April 2 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that the report of the Company's...

Boston Life Sciences To Host 2006 4th Quarter Conference Call

HOPKINTON, Mass., March 29 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that they will host a conference...

Boston Life Sciences Completes Final License Fee Payment for Exclusive, Worldwide Rights to Develop and Commercialize Phase II S

Company gains sole responsibility for Cethrin development HOPKINTON, Mass., March 27 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc...

Boston Life Sciences Enters Into $15 Million Convertible Promissory Note Purchase Agreement and Amends Existing Promissory Notes

HOPKINTON, Mass., March 26 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that on March 22, 2007, it entered...

Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of

HOPKINTON, Mass., March 22 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI), a biotechnology company focused on diagnostic and...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Boston Life Sciences (MM) (BLSI)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BLSI News

Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.

Boston Life Sciences, Inc. Announces Webcast of 2007 Annual Meeting

Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program

Boston Life Sciences to Host 2007 1st Quarter Conference Call

Boston Life Sciences Raises $6 Million Through Issuance of a Convertible Promissory Note to a New Fund

Boston Life Sciences, Inc. to Present at the 2007 Biotechnology Industry Organization's (BIO) Annual BIO International Conventio

Boston Life Sciences Reports New Option Grants Under NASDAQ Market Rule 4350

Boston Life Sciences, Inc. Announces Presentation of Cethrin(R) Phase I/IIa 6-Month Results at 75th Annual Meeting of the Americ

Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer

Boston Life Sciences, Inc. Announces Data to be Presented on Cethrin(R) for Spinal Cord Injury at the 2007 American Association

Boston Life Sciences, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K

Boston Life Sciences To Host 2006 4th Quarter Conference Call

Boston Life Sciences Completes Final License Fee Payment for Exclusive, Worldwide Rights to Develop and Commercialize Phase II S

Boston Life Sciences Enters Into $15 Million Convertible Promissory Note Purchase Agreement and Amends Existing Promissory Notes

Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of

BLSI Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Boston Life Sciences (MM) (BLSI) News

Boston Life Sciences (MM) (BLSI)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BLSI News

Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.

Boston Life Sciences, Inc. Announces Webcast of 2007 Annual Meeting

Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program

Boston Life Sciences to Host 2007 1st Quarter Conference Call

Boston Life Sciences Raises $6 Million Through Issuance of a Convertible Promissory Note to a New Fund

Boston Life Sciences, Inc. to Present at the 2007 Biotechnology Industry Organization's (BIO) Annual BIO International Conventio

Boston Life Sciences Reports New Option Grants Under NASDAQ Market Rule 4350

Boston Life Sciences, Inc. Announces Presentation of Cethrin(R) Phase I/IIa 6-Month Results at 75th Annual Meeting of the Americ

Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer

Boston Life Sciences, Inc. Announces Data to be Presented on Cethrin(R) for Spinal Cord Injury at the 2007 American Association

Boston Life Sciences, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K

Boston Life Sciences To Host 2006 4th Quarter Conference Call

Boston Life Sciences Completes Final License Fee Payment for Exclusive, Worldwide Rights to Develop and Commercialize Phase II S

Boston Life Sciences Enters Into $15 Million Convertible Promissory Note Purchase Agreement and Amends Existing Promissory Notes

Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of

BLSI Discussion

Your Recent History